Drug Profile
INO 1800
Alternative Names: INO-1800; INO-1800 SynCon® immunotherapy; RG-7944Latest Information Update: 27 Apr 2021
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Class DNA vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for phase-I development in Hepatitis-B in Australia, USA, Hong Kong, Puerto Rico, Philippines, Singapore, Taiwan, Thailand, New Zealand (IM)
- 01 May 2018 Inovio Pharmaceuticals completes a phase I trial in Hepatitis B in Thailand, Taiwan, Philippines, Singapore, Puerto Rico, USA, Hong Kong, Australia (IM) (NCT02431312)
- 11 Apr 2018 INO 1800 is available for licensing as of 14 Mar 2018. https://www.inovio.com/